• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ALX Oncology Holdings Inc. - Common Stock (NQ:ALXO)

2.210 +0.080 (+3.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ALX Oncology Holdings Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 27, 2026
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
February 19, 2026
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
February 19, 2026
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Pricing of Underwritten Offering
January 30, 2026
From ALX Oncology
Via GlobeNewswire
News headline image
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
January 30, 2026
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 08, 2026
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
January 08, 2026
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
December 07, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
From FN Media Group LLC
Via GlobeNewswire
News headline image
ALX Oncology to Present at Upcoming Investor Conferences
November 18, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 07, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
October 30, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
October 23, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 03, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
September 12, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Participate in Upcoming Investor Conferences in September
August 29, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
August 19, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 12, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
August 05, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
May 30, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
May 20, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
May 13, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 08, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
May 02, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
April 25, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
April 25, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
April 07, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 06, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
March 05, 2025
From ALX Oncology
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap